secwatch.observer — SEC 8-K summary
======================================

Issuer:     Immunovant, Inc. (IMVT)
CIK:        0001764013
Form:       8-K
Filed at:   2022-02-04T23:59:59+00:00
Accession:  0001764013-22-000029
Event type: earnings
Sentiment:  negative
Materiality: 0.55
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Immunovant Q3 net loss widens to $41.4M; cash at $527M; clinical pause continues
--------------------------------------------------------------------------------

- Net loss of $41.4M ($0.36 per share) for Dec 2021 quarter vs. $31.8M ($0.32) a year ago.
- R&D expenses rose to $29.8M from $21.1M, driven by clinical study costs and manufacturing.
- Cash and equivalents of $527.0M as of Dec 31, 2021; no revenue reported.
- G&A expenses increased to $11.5M from $10.5M year-over-year, partly due to stock-based compensation.
- Clinical trial activities remain paused due to previously announced voluntary hold.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1764013/000176401322000029/0001764013-22-000029-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1764013/000176401322000029/imvt-20220204.htm
  HTML page:      https://secwatch.observer/filing/0001764013-22-000029

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer